Intelligent bio solutions highlights continued expansion with strategic partnership in spain and andorra

Inbs set to capitalize on growing spanish drug testing market, anticipated to reach $448 million by 2030 major spanish accounts currently require 1,000 drug testing cartridges per month new york, march 27, 2025 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) ("inbs" or the "company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has expanded access to its fingerprint drug testing in spain and andorra through a strategic collaboration with detecto, a division of spanish distributor mtb distribuciones tecnologicas sl ("mtb"). mtb established detecto following decades of experience in clinical distribution, recognizing the market's evolving needs and increasing demand for drug testing across various sectors.
INBS Ratings Summary
INBS Quant Ranking